

# Adam Bucki

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7396980/publications.pdf>

Version: 2024-02-01

53  
papers

1,015  
citations

361045

20  
h-index

476904

29  
g-index

54  
all docs

54  
docs citations

54  
times ranked

1322  
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel multi-target-directed ligands for Alzheimer's disease: Combining cholinesterase inhibitors and 5-HT <sub>6</sub> receptor antagonists. Design, synthesis and biological evaluation. <i>European Journal of Medicinal Chemistry</i> , 2016, 124, 63-81.	2.6	72
2	Ligand-Optimized Homology Models of D <sub>1</sub> and D <sub>2</sub> Dopamine Receptors: Application for Virtual Screening. <i>Journal of Chemical Information and Modeling</i> , 2013, 53, 638-648.	2.5	59
3	Novel Arylsulfonamide Derivatives with 5-HT <sub>6</sub> /5-HT <sub>7</sub> Receptor Antagonism Targeting Behavioral and Psychological Symptoms of Dementia. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 4543-4557.	2.9	58
4	Metabolic carbonyl reduction of anthracyclines – role in cardiotoxicity and cancer resistance. Reducing enzymes as putative targets for novel cardioprotective and chemosensitizing agents. <i>Investigational New Drugs</i> , 2017, 35, 375-385.	1.2	46
5	Novel Multitarget-Directed Ligands Aiming at Symptoms and Causes of Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2018, 9, 1195-1214.	1.7	44
6	Novel butanehydrazide derivatives of purine-2,6-dione as dual PDE4/7 inhibitors with potential anti-inflammatory activity: Design, synthesis and biological evaluation. <i>European Journal of Medicinal Chemistry</i> , 2018, 146, 381-394.	2.6	37
7	Idalopirdine – a small molecule antagonist of 5-HT <sub>6</sub> with therapeutic potential against obesity. <i>Metabolic Brain Disease</i> , 2015, 30, 1487-1494.	1.4	35
8	Phosphodiesterase 10 Inhibitors - Novel Perspectives for Psychiatric and Neurodegenerative Drug Discovery. <i>Current Medicinal Chemistry</i> , 2018, 25, 3455-3481.	1.2	35
9	Novel spirohydantoin derivative as a potent multireceptor-active antipsychotic and antidepressant agent. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 3436-3447.	1.4	32
10	Antidepressant- and anxiolytic-like activity of 7-phenylpiperazinylalkyl-1,3-dimethyl-purine-2,6-dione derivatives with diversified 5-HT <sub>1A</sub> receptor functional profile. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 212-221.	1.4	31
11	Idalopirdine, a selective 5-HT <sub>6</sub> receptor antagonist, reduces food intake and body weight in a model of excessive eating. <i>Metabolic Brain Disease</i> , 2018, 33, 733-740.	1.4	30
12	Synergistic anticancer activity of doxorubicin and piperlongumine on DU-145 prostate cancer cells – The involvement of carbonyl reductase 1 inhibition. <i>Chemico-Biological Interactions</i> , 2019, 300, 40-48.	1.7	30
13	Evaluation of 1-arylpiperazine derivative of hydroxybenzamides as 5-HT <sub>1A</sub> and 5-HT <sub>7</sub> serotonin receptor ligands: An experimental and molecular modeling approach. <i>Journal of Heterocyclic Chemistry</i> , 2011, 48, 192-198.	1.4	29
14	Structure-activity relationships and molecular studies of novel arylpiperazinylalkyl purine-2,4-diones and purine-2,4,8-triones with antidepressant and anxiolytic-like activity. <i>European Journal of Medicinal Chemistry</i> , 2015, 97, 142-154.	2.6	27
15	Design, synthesis, and biological evaluation of fluorinated imidazo[1,2-a]pyridine derivatives with potential antipsychotic activity. <i>European Journal of Medicinal Chemistry</i> , 2016, 124, 456-467.	2.6	27
16	Novel amide derivatives of 1,3-dimethyl-2,6-dioxapurin-7-yl-alkylcarboxylic acids as multifunctional TRPA1 antagonists and PDE4/7 inhibitors: A new approach for the treatment of pain. <i>European Journal of Medicinal Chemistry</i> , 2018, 158, 517-533.	2.6	27
17	Novel 5-HT <sub>6</sub> receptor antagonists/D <sub>2</sub> receptor partial agonists targeting behavioral and psychological symptoms of dementia. <i>European Journal of Medicinal Chemistry</i> , 2015, 92, 221-235.	2.6	26
18	Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1 <i>H</i> -indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7483-7501.	2.9	25

#	ARTICLE	IF	CITATIONS
19	Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 1: Overview of the Chemical and Biological Research. <i>Current Drug Targets</i> , 2018, 20, 122-143.	1.0	23
20	Synthesis and biological evaluation of 2-fluoro and 3-trifluoromethyl-phenyl-piperazinylalkyl derivatives of 1 <i>H</i> -imidazo[2,1- <i>f</i> ]purine-2,4(3 <i>H</i> ,8 <i>H</i> )-dione as potential antidepressant agents. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2016, 31, 10-24.	2.5	21
21	Novel Aryloxyethyl Derivatives of 1-(1-Benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) Phosphorylation-Preferring Serotonin 5-HT <sub>1A</sub> Receptor-Biased Agonists with Robust Antidepressant-like Activity. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 2750-2771.	2.9	21
22	Novel and effective synthesis protocol of AgNPs functionalized using L-cysteine as a potential drug carrier. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2018, 391, 123-130.	1.4	19
23	Novel anilide and benzamide derivatives of arylpiperazinylalkanoic acids as 5-HT <sub>1A</sub> /5-HT <sub>7</sub> receptor antagonists and phosphodiesterase 4/7 inhibitors with procognitive and antidepressant activity. <i>European Journal of Medicinal Chemistry</i> , 2020, 201, 112437.	2.6	19
24	Anti-Alzheimer's multitarget-directed ligands with serotonin 5-HT <sub>6</sub> antagonist, butyrylcholinesterase inhibitory, and antioxidant activity. <i>Archiv Der Pharmazie</i> , 2019, 352, e1900041.	2.1	16
25	New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases. <i>European Journal of Medicinal Chemistry</i> , 2021, 209, 112854.	2.6	16
26	Novel Mannich Bases, 5-Arylimidazolidine-2,4-dione Derivatives with Dual 5-HT <sub>1A</sub> Receptor and Serotonin Transporter Affinity. <i>Archiv Der Pharmazie</i> , 2013, 346, 98-109.	2.1	15
27	3-Aminomethyl Derivatives of 2-Phenylimidazo[1,2- <i>a</i> ]-pyridine as Positive Allosteric Modulators of GABA <sub>A</sub> Receptor with Potential Antipsychotic Activity. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1291-1298.	1.7	15
28	Discovery of Novel pERK1/2- or $\beta$ -Arrestin-Preferring 5-HT <sub>1A</sub> Receptor-Biased Agonists: Diversified Therapeutic-like versus Side Effect Profile. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 10946-10971.	2.9	15
29	Cinnamic acid derivatives as chemosensitising agents against DOX-treated lung cancer cells – Involvement of carbonyl reductase 1. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 154, 105511.	1.9	14
30	Synthesis and biological evaluation of 1 <i>N</i> -aryl piperazine derivatives of 4,4-dimethylisoquinoline-1,3(2 <i>H</i> ,4 <i>H</i> )-dione as potential antiplatelet agents. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2018, 33, 536-545.	2.5	13
31	Development and crystallography-aided SAR studies of multifunctional BuChE inhibitors and 5-HT <sub>6R</sub> antagonists with $\beta$ -amyloid anti-aggregation properties. <i>European Journal of Medicinal Chemistry</i> , 2021, 225, 113792.	2.6	13
32	Discovery of 1-(phenylsulfonyl)-1 <i>H</i> -indole-based multifunctional ligands targeting cholinesterases and 5-HT <sub>6</sub> receptor with anti-aggregation properties against amyloid-beta and tau. <i>European Journal of Medicinal Chemistry</i> , 2021, 225, 113783.	2.6	11
33	Determination of lipophilicity of 1 <i>N</i> -(4-phenylpiperazine) derivatives of 1 <i>N</i> -benzylamides using chromatographic and computational methods. <i>Biomedical Chromatography</i> , 2008, 22, 428-432.	0.8	10
34	Arylpiperazinylalkyl derivatives of 8-amino-1,3-dimethylpurine-2,6-dione as novel multitarget 5-HT/D receptor agents with potential antipsychotic activity. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2016, 31, 1048-1062.	2.5	10
35	Aminoalkyl Derivatives of 8-Alkoxy-purine-2,6-diones: Multifunctional 5-HT <sub>1A</sub> /5-HT <sub>7</sub> Receptor Ligands and PDE Inhibitors with Antidepressant Activity. <i>Archiv Der Pharmazie</i> , 2016, 349, 889-903.	2.1	9
36	Novel multitarget 5-arylidenhydantoin with arylpiperazinealkyl fragment: Pharmacological evaluation and investigation of cytotoxicity and metabolic stability. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 4163-4173.	1.4	8

#	ARTICLE	IF	CITATIONS
37	Characteristics of metabolic stability and the cell permeability of 2-pyrimidinyl-piperazinylalkyl derivatives of 1H-imidazo[2,1-b]purine-2,4(3H,8H)-dione with antidepressant and anxiolytic activities. <i>Chemical Biology and Drug Design</i> , 2019, 93, 511-521.	1.5	8
38	Synthesis and activity of di- or trisubstituted N-(phenoxyalkyl)- or N-{2-[2-(phenoxy)ethoxy]ethyl}piperazine derivatives on the central nervous system. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 2039-2049.	1.0	7
39	In Vitro and In Silico ADME-Tox Profiling and Safety Significance of Multifunctional Monoamine Oxidase Inhibitors Targeting Neurodegenerative Diseases. <i>ACS Chemical Neuroscience</i> , 2020, 11, 3793-3801.	1.7	7
40	New Arylpiperazinylalkyl Derivatives of 8-Alkoxy-purine-2,6-dione and Dihydro[1,3]oxazolo[2,3-f]purinedione Targeting the Serotonin 5-HT <sub>1A</sub> and 5-HT <sub>2A</sub> and Dopamine D <sub>2</sub> Receptors. <i>Archiv Der Pharmazie</i> , 2015, 348, 242-253.	2.1	6
41	Synthesis and Pharmacological Activity of a New Series of 1-(1H-indol-4-yl)-3-(2-(methoxyphenoxy)ethylamino)propanol Analogs. <i>Archiv Der Pharmazie</i> , 2016, 349, 211-223.		
42	Impact of N-Alkylamino Substituents on Serotonin Receptor (5-HTR) Affinity and Phosphodiesterase 10A (PDE10A) Inhibition of Isoindole-1,3-dione Derivatives. <i>Molecules</i> , 2020, 25, 3868.	1.7	6
43	Multifunctional Arylsulfone and Arylsulfonamide-Based Ligands with Prominent Mood-Modulating Activity and Benign Safety Profile, Targeting Neuropsychiatric Symptoms of Dementia. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 12603-12629.	2.9	5
44	The study of the lipophilicity of 4-phenylpiperazine-1-yl and 3-phenylphthalimidobutyramides using chromatographic and computational methods. <i>Biomedical Chromatography</i> , 2008, 22, 688-694.	0.8	4
45	Synthesis of N-(phenoxyalkyl)-, N-{2-[2-(phenoxy)ethoxy]ethyl}- or N-(phenoxyacetyl)piperazine Derivatives and Their Activity Within the Central Nervous System. <i>ChemistrySelect</i> , 2019, 4, 9381-9391.	0.7	4
46	Multifunctional 6-fluoro-3-[3-(pyrrolidin-1-yl)propyl]-1,2-benzoxazoles targeting behavioral and psychological symptoms of dementia (BPSD). <i>European Journal of Medicinal Chemistry</i> , 2020, 191, 112149.	2.6	4
47	Carbonyl reduction pathway in hepatic in vitro metabolism of anthracyclines: Impact of structure on biotransformation rate. <i>Toxicology Letters</i> , 2021, 342, 50-57.	0.4	4
48	Design, synthesis, and behavioral evaluation of dual-acting compounds as phosphodiesterase type 10A (PDE10A) inhibitors and serotonin ligands targeting neuropsychiatric symptoms in dementia. <i>European Journal of Medicinal Chemistry</i> , 2022, 233, 114218.	2.6	4
49	Structural Modeling of TRPA1 Ion Channel—Determination of the Binding Site for Antagonists. <i>Molecules</i> , 2022, 27, 3077.	1.7	4
50	Cinnamide derivatives with 4-hydroxypiperidine moiety enhance effect of doxorubicin to cancer cells and protect cardiomyocytes against drug-induced toxicity through CBR1 inhibition mechanism. <i>Life Sciences</i> , 2022, 305, 120777.	2.0	3
51	Novel serotonin 5-HT <sub>2A</sub> receptor antagonists derived from 4-phenylcyclohexane-5-spiro- and 5-methyl-5-phenyl-hydantoin, for use as potential antiplatelet agents. <i>Pharmacological Reports</i> , 2021, 73, 1361-1372.	1.5	2
52	NEW SPIROHYDANTOIN DERIVATIVES - SYNTHESIS, PHARMACOLOGICAL EVALUATION, AND MOLECULAR MODELING STUDY. <i>Acta Poloniae Pharmaceutica</i> , 2016, 73, 1545-1554.	0.3	2
53	Functional selectivity—chance for better and safer drugs?. <i>Postepy Psychiatrii I Neurologii</i> , 2017, 26, 165-178.	0.2	1